Paper Details

  1. Home
  2. Paper Details

Single-center experience with use of letermovir for CMV prophylaxis or treatment in thoracic organ transplant recipients.

Author: AhmadKareem, AryalShambhu, BrownAnne Whitney, ChunJessica, CochraneAdam, DesaiShashank, FregosoMargaret, KatugahaShalika B, KingChristopher, MarinakLauren, NathanSteven D, ShlobinOksana A

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

Letermovir has been shown to be effective in preventing CMV infection in allogeneic hematopoietic cell transplantation. However, there is currently no data on its efficacy in thoracic organ transplant recipients.
Paper Details　
Original Abstract of the Article :
Cytomegalovirus (CMV) infection is common in thoracic organ transplant recipients. Valganciclovir and ganciclovir are used for both prophylaxis and treatment of this infection, but intolerance and treatment failure are common. Letermovir has been demonstrated to reduce the risk of CMV infection when...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1111/tid.13166

データ提供：米国国立医学図書館（NLM）

Letermovir: A New Weapon Against CMV Infection in Thoracic Transplant Recipients

Cytomegalovirus (CMV) infection is a common complication following thoracic organ transplantation, posing a significant threat to transplant recipients. This research investigates the effectiveness of letermovir, a novel antiviral agent, in preventing or treating CMV infection in thoracic transplant recipients. The authors share their single-center experience using letermovir for CMV prophylaxis and treatment.

Letermovir Shows Promise for CMV Prophylaxis and Treatment in Thoracic Transplant Recipients

The study suggests that letermovir may be a promising therapeutic option for both prophylaxis and treatment of CMV infection in thoracic transplant recipients. This research offers valuable insights into the potential use of letermovir in managing CMV infections in this vulnerable population.

A Desert Oasis for Transplant Recipients

Imagine CMV infection as a lurking desert predator, threatening the health of transplant recipients. This research, like a camel discovering a hidden oasis, explores the potential of letermovir to combat this infection and create a more secure environment for those who have undergone thoracic transplantation.

Dr. Camel's Conclusion

CMV infection can be a dangerous desert predator, lurking in the shadows and threatening the health of transplant recipients. This research, like a camel discovering a new source of water, highlights the potential of letermovir to combat this infection, offering hope for a healthier and more secure journey through the desert of post-transplant life.

Date :
  1. Date Completed 2020-04-30
  2. Date Revised 2020-04-30
Further Info :

Pubmed ID

31487755

DOI: Digital Object Identifier

10.1111/tid.13166

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.